MYC and lymphoma: Given our desire to target Myc family proteins and the signal of activity in Myc‐driven adult tumors treated with fimepinostat, we developed a multicenter, open‐label, Phase 1 study of fimepinostat in children and young adults with relapsed or refractory solid tumors, CNS tumors, and lymphoma.